{"id":"W3205063602","doi":"10.1016/s1470-2045(21)00494-0","title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health; National Cancer Institute; Medical Research Council; National Institute for Health and Care Research; Bristol-Myers Squibb","keywords":"Azacitidine; Medicine; IDH2; Internal medicine; Myeloid leukaemia; Population; Clinical endpoint; Myeloid leukemia; Oncology; Myeloid; Clinical trial; Surgery; IDH1; Mutant; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001491575,0.0006086588,0.002431788,0.0003376587,0.0002368311,0.0000861112,0.000464904,0.000439048,0.0004567417],"category_scores_gemma":[0.001719781,0.0004300968,0.0001829612,0.001008177,0.0007420274,0.0002654545,0.0003565848,0.00147935,0.00005629805],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002013408,"about_ca_system_score_gemma":0.00223267,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001974592,"about_ca_topic_score_gemma":0.0006142049,"domain_scores_codex":[0.9947317,0.00100448,0.0009818564,0.0009916425,0.0008450841,0.001445256],"domain_scores_gemma":[0.9949762,0.002653814,0.0003834792,0.001077375,0.0003838055,0.0005253468],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9302837,0.007258024,0.0004327708,0.0001087899,0.000951082,0.01012547,0.001186082,0.00001684221,0.01141405,0.0001049976,0.005253643,0.03286457],"study_design_scores_gemma":[0.942632,0.02247644,0.0003165741,0.0001522559,0.0007895258,0.0005782007,0.0004023981,0.0004704435,0.007169798,0.00006943748,0.02448104,0.0004618547],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9825436,0.0005975175,0.0001388141,0.009611357,0.0006626858,0.003648409,0.0002592845,0.0001305695,0.002407724],"genre_scores_gemma":[0.9904414,0.001381673,0.001712124,0.002204603,0.00205071,0.0005776241,0.0009014416,0.0001286523,0.0006018109],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03240271,"threshold_uncertainty_score":0.9998151,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04659093949864618,"score_gpt":0.3497902769540706,"score_spread":0.3031993374554244,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}